105 related articles for article (PubMed ID: 7970734)
1. The MTS1 gene is frequently mutated in primary human esophageal tumors.
Zhou X; Tarmin L; Yin J; Jiang HY; Suzuki H; Rhyu MG; Abraham JM; Meltzer SJ
Oncogene; 1994 Dec; 9(12):3737-41. PubMed ID: 7970734
[TBL] [Abstract][Full Text] [Related]
2. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma.
Mori T; Miura K; Aoki T; Nishihira T; Mori S; Nakamura Y
Cancer Res; 1994 Jul; 54(13):3396-7. PubMed ID: 8012957
[TBL] [Abstract][Full Text] [Related]
3. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.
Caldas C; Hahn SA; da Costa LT; Redston MS; Schutte M; Seymour AB; Weinstein CL; Hruban RH; Yeo CJ; Kern SE
Nat Genet; 1994 Sep; 8(1):27-32. PubMed ID: 7726912
[TBL] [Abstract][Full Text] [Related]
4. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines.
Liu Q; Yan YX; McClure M; Nakagawa H; Fujimura F; Rustgi AK
Oncogene; 1995 Feb; 10(3):619-22. PubMed ID: 7845688
[TBL] [Abstract][Full Text] [Related]
5. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas.
Huang Y; Meltzer SJ; Yin J; Tong Y; Chang EH; Srivastava S; McDaniel T; Boynton RF; Zou ZQ
Cancer Res; 1993 Apr; 53(8):1889-94. PubMed ID: 8467510
[TBL] [Abstract][Full Text] [Related]
6. No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas.
Sun Y; Hildesheim A; Lanier AE; Cao Y; Yao KT; Raab-Traub N; Yang CS
Oncogene; 1995 Feb; 10(4):785-8. PubMed ID: 7862458
[TBL] [Abstract][Full Text] [Related]
7. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
9. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.
Sartor M; Steingrimsdottir H; Elamin F; Gäken J; Warnakulasuriya S; Partridge M; Thakker N; Johnson NW; Tavassoli M
Br J Cancer; 1999 Apr; 80(1-2):79-86. PubMed ID: 10389982
[TBL] [Abstract][Full Text] [Related]
10. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
Packenham JP; Taylor JA; White CM; Anna CH; Barrett JC; Devereux TR
Clin Cancer Res; 1995 Jul; 1(7):687-90. PubMed ID: 9816033
[TBL] [Abstract][Full Text] [Related]
11. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
Liu Q; Neuhausen S; McClure M; Frye C; Weaver-Feldhaus J; Gruis NA; Eddington K; Allalunis-Turner MJ; Skolnick MH; Fujimura FK
Oncogene; 1995 Mar; 10(6):1061-7. PubMed ID: 7700630
[TBL] [Abstract][Full Text] [Related]
12. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population.
Biden K; Young J; Buttenshaw R; Searle J; Cooksley G; Xu DB; Leggett B
Hepatology; 1997 Mar; 25(3):593-7. PubMed ID: 9049204
[TBL] [Abstract][Full Text] [Related]
13. Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV.
Olshan AF; Weissler MC; Pei H; Conway K; Anderson S; Fried DB; Yarbrough WG
Oncogene; 1997 Feb; 14(7):811-8. PubMed ID: 9047388
[TBL] [Abstract][Full Text] [Related]
14. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck.
Zhang SY; Klein-Szanto AJ; Sauter ER; Shafarenko M; Mitsunaga S; Nobori T; Carson DA; Ridge JA; Goodrow TL
Cancer Res; 1994 Oct; 54(19):5050-3. PubMed ID: 7923115
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers.
Huang Y; Boynton RF; Blount PL; Silverstein RJ; Yin J; Tong Y; McDaniel TK; Newkirk C; Resau JH; Sridhara R; Reid BJ; Meltzer SJ
Cancer Res; 1992 Dec; 52(23):6525-30. PubMed ID: 1423299
[TBL] [Abstract][Full Text] [Related]
16. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
17. p16INK4 gene mutation and allelic loss of chromosome 9p21-22 in Taiwanese hepatocellular carcinoma.
Chen TC; Hsieh LL; Kuo TT; Ng KF; Wu Chou YH; Jeng LB; Chen MF
Anticancer Res; 2000; 20(3A):1621-6. PubMed ID: 10928081
[TBL] [Abstract][Full Text] [Related]
18. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
Pollock PM; Pearson JV; Hayward NK
Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
[TBL] [Abstract][Full Text] [Related]
19. p16MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx.
Jares P; Fernández PL; Nadal A; Cazorla M; Hernández L; Pinyol M; Hernández S; Traserra J; Cardesa A; Campo E
Oncogene; 1997 Sep; 15(12):1445-53. PubMed ID: 9333020
[TBL] [Abstract][Full Text] [Related]
20. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
